AbbVie Analysts Increase Their Forecasts After Upbeat Earnings

+1.19% Pre

AbbVie, Inc.

ABBV

188.76

+1.19%

0.00% Pre

AbbVie Inc (NYSE:ABBV) reported better-than-expected earnings for its third quarter and raised its profit outlook on Friday.

AbbVie reported quarterly adjusted EPS of $2.95, down 19.4% Y/Y, beating the consensus of $2.88. Overall sales decreased 6% Y/Y (down 5.8% on an operational basis) to $13.93 billion, beating the consensus of $13.70 billion.

AbbVie raised its FY23 adjusted EPS guidance from $10.86-$11.06 to $11.19-$11.23 versus the consensus of $11.05. The company also raised its FY24 adjusted EPS guidance floor from $10.70 to $11.00 compared to the consensus of $11.07.

AbbVie shares rose 2.8% to trade at $142.85 on Monday.

These analysts made changes to their price targets on AbbVie following earnings announcement.

Barclays raised the price target on AbbVie from $160 to $170. Barclays analyst Carter Gould upgraded the stock from Equal-Weight to Overweight.
Morgan Stanley increased the price target on AbbVie from $193 to $196. Morgan Stanley analyst Terence Flynn maintained an Overweight rating.

Also Check This Out: Insiders Buying M&T Bank And 3 Other Stocks

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.